Creso Pharma’s target acquisition company announces expansion into other psychedelic compounds
      
        
  
  
  
     
      Finfeed
    
  
        
          
  
  
    
      
        Archived
    
  
  
        
        Apr 12, 2021
      
      Creso Pharma Limited (ASX: CPH, FRA:1X8) has provided an update regarding target acquisition company, Halucenex Life Sciences, outlining its entry into an advisory agreement with Growing Together Research Inc. (GTR) to explore the genome sequencing of natural psilocybe.